Pasar al contenido principal

CONEXIONES ENTRE LAS ALTERACIONES EN EL COMPLEJO REMODELADOR SWI-SNF Y LAS RUTAS TUMORALES CANONICAS EN CANCER DE PULMON

PID2020-117539GB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2020
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE CANTABRIA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of SWI/SNF chromatin remodeling genes in lung cancer development

  • Monterde, Beatriz
  • Varela, Ignacio
SWI/SNF family of chromatin remodeling complexes uses the energy of ATP to change the structure of DNA, playing key roles in DNA regulation and repair. It is estimated that up to 25% of all human cancers contain alterations in SWI/SNF, although the precise molecular mechanisms for their involvement in tumor progression are largely unknown. Despite the improvements achieved in the last decades on our knowledge of lung cancer molecular biology, it remains the major cause of cancer-related deaths worldwide and it is in urgent need for new therapeutic alternatives. We and others have described recurrent alterations in different SWI/SNF genes in nearly 20% of lung cancer patients, some of them with a significant association with worse prognosis, indicating an important role of SWI/SNF in this fatal disease. These alterations might be therapeutically exploited, as it has been shown in cellular and animal models with the use of EGFR inhibitors, DNA-damaging agents and several immunotherapy approaches. Therefore, a better knowledge of the molecular mechanisms regulated by SWI/SNF alterations in lung cancer might be translated into a therapeutic improvement of this frequently lethal disease. In this review, we summarize all the evidence of SWI/SNF alterations in lung cancer, the current knowledge about the potential mechanisms involved in their tumorigenic role, as well as the results that support a potential exploitation of these alterations to improve the treatment of lung cancer patients., This work is supported by the Spanish Ministerio de Ciencia e Innovación (MCIN/ AEI /10.13039/501100011033. ref PID2020-117539GB-I00). B.M is awardee of the Ayudas para la formación de profesorado universitario (FPU, Ministerio de Ciencia, Innovación y Universidades, Spain).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

MYC directly transactivates CR2/CD21, the receptor of the Epstein-Barr virus, enhancing the viral infection of Burkitt lymphoma cells

  • Molina Hoyo, Ester
  • García-Gutiérrez, Lucía
  • Junco, Vanessa
  • Perez-Olivares, Mercedes
  • Yébenes, Virginia G. de
  • Blanco, Rosa
  • Quevedo, Laura
  • Acosta, Juan C.
  • Marín, Ana V.
  • Ulgiati, Daniela
  • Merino, Ramón
  • Delgado, M. Dolores
  • Varela, Ignacio
  • Regueiro, José R.
  • Moreno de Alborán, Ignacio
  • Ramiro, Almudena R.
  • León, Javier
MYC is an oncogenic transcription factor dysregulated in about half of total human tumors. While transcriptomic studies reveal more than 1000 genes regulated by MYC, a much smaller fraction of genes is directly transactivated by MYC. Virtually all Burkitt lymphoma (BL) carry chromosomal translocations involving MYC oncogene. Most endemic BL and a fraction of sporadic BL are associated with Epstein–Barr virus (EBV) infection. The currently accepted mechanism is that EBV is the BL-causing agent inducing MYC translocation. Herein we show that the EBV receptor, CR2 (also called CD21), is a direct MYC target gene. This is based on several pieces of evidence: MYC induces CR2 expression in both proliferating and arrested cells and in the absence of protein synthesis, binds the CR2 promoter and transactivates CR2 in an E-box-dependent manner. Moreover, using mice with conditional MYC ablation we show that MYC induces CR2 in primary B cells. Importantly, modulation of MYC levels directly correlates with EBV’s ability of infection in BL cells. Altogether, in contrast to the widely accepted hypothesis for the correlation between EBV and BL, we propose an alternative hypothesis in which MYC dysregulation could be the first event leading to the subsequent EBV infection., The work was supported by grants PID2020-115903GB-100 to JL and MDD, RTI2018-095673-B-I00 to JRR, PID2019-107551RB-I00 to VG-Y, PID2020-119567RB-I00 to RM, PID2020-117539GB-I00 to IV and PID2019-106773RB-I00 to ARR, all funded by MCIN/AEI/10.13039/501100011033/, Spanish Government, and by “FEDER, Una manera de hacer Europa”, European Union, and by La Caixa HR17-0244 grant to AR. LQ and VJ were recipients of F.P.U. program and Universidad de Cantabria fellowships, respectively. LG-G was a fellow of the Maria Zambrano program, Spanish Government.